Clinical Study

A Phase 1B/2, Open-Label, Multicentre Study Assessing The Safety, Tolerability, Pharmacokinetics, And Preliminary Anti-Tumour Activity Of Medi4736 In Combination With Azd9150 Or Azd5069 In Patients With Advanced Solid Malignancies And Subsequently C

Posted Date: May 12, 2017

  • Investigator: Trisha Wise-Draper
  • Co-Investigator: Alison Kastl
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The main purpose of this study is to see if the AZD9150 and AZD5069 study drugs (alone or in combination with MEDI4736) shrink tumors like yours and by how much. This study is also being done to measure levels of the study drugs in the blood at different

Criteria:

To Be Eligible, Patients Must Have Squamous Cell Carcinoma Of The Head And Neck That Is Either Recurrent And/Or Metastatic And Is Not Able To Be Cured By Surgery Or Radiation.

Keywords:

Head And Neck, Cancer, D5660c00004, Phase I, Solid Tumor

For More Information:

Uc Cancer Institute
5135847698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.